LB Pharmaceuticals Inc Common Stock
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Heather D. Turner
- Full Time Employees
- 49
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- One Pennsylvania Plaza New York NY United States of America 10119
- IPO Date
- Sep 11, 2025
- CIK
- 0001691082
- Website
- lbpharma.us
- Similar Companies
- Business
- LB Pharmaceuticals Inc (LBRX), a clinical-stage biopharmaceutical company founded in 2015 and headquartered at One Pennsylvania Plaza, Suite 1025, New York, New York, develops novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The company builds a pipeline leveraging the broad therapeutic potential of its lead product candidate, LB-102, an oral small molecule and new chemical entity that is a methylated derivative of amisulpride, a second-generation antipsychotic approved in over 50 countries; LB-102 is Phase 3-ready for acute schizophrenia, having reported positive top-line Phase 2 results in January 2025 demonstrating a statistically significant change in the Positive and Negative Syndrome Scale score, completed Phase 1 for bipolar I depression, and advancing an investigational long-acting injectable (LAI) formulation. LB Pharmaceuticals operates in the biotechnology sector, targeting patients with severe psychiatric disorders through clinical trials conducted primarily in the United States. In September 2025, the company completed a landmark initial public offering on Nasdaq, raising $285 million to fund a Phase 3 trial for LB-102 in schizophrenia starting early 2026, a Phase 2 trial for bipolar depression, and further pipeline development, following prior private financing exceeding $120 million including a $75 million Series C round.
Company News
LB Pharmaceuticals to Participate in Upcoming Investor Events
LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment
LB Pharmaceuticals Inc (NASDAQ:LBRX) Stock Has Average Target Price of $49.62
LB Pharmaceuticals: One Methyl Group, Two Enantiomers, And A Bullish $5 Billion Opportunity
LB Pharmaceuticals Appoints Susan G. Kozauer, M.D.
IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?
LB Pharmaceuticals to Participate in Upcoming September Investor Events
LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer
Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes
LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
LB Pharmaceuticals Announces $150 Million Private Placement
LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations
LB Pharmaceuticals to Participate in Upcoming June Investor Events
All You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to Buy
LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia
LB Pharmaceuticals Inc (LBRX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript